Boston, MA -- (SBWIRE) -- 01/21/2015 -- Sickle-cell anemia is a disease characterized by the presence of sickle-shaped erythrocytes. While normal erythrocytes have a life span of 120 days, sickle-shaped erythrocytes die within 10 to 20 days. The bone marrow is unable to compensate for the excessive loss of erythrocytes, thereby leading to anemia. It is an inheritable disorder passed on across generations. The prevalence of the sickle-cell gene varies between different ethnic groups and geographical locations.

TechNavio's analysts forecast the Sickle-cell Anemia Therapeutics market in the US to grow at a CAGR of 17.10 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Sickle-cell Anemia Therapeutics market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of the US FDA-approved drugs used for the treatment of sickle-cell anemia.

View Full Report Details and Table of Contents

TechNavio's report, Sickle-cell Anemia Therapeutics Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the Sickle-cell Anemia Therapeutics market landscape in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

- Bristol-Myers Squibb

Future Prominent Vendors

- Baxter
- Bluebird Bio
- Daiichi Sankyo
- Eli Lilly
- Emmaus Medical
- GlycoMimetics
- HemaQuest Pharmaceuticals
- Mast Therapeutics
- Merck Sharp & Dohme
- Pfizer
- Selexys Pharmaceuticals

Market Driver

- Unmet Medical Needs
- For a full, detailed list, view our report

Market Challenge

- Side Effects Associated with Current Therapies
- For a full, detailed list, view our report

Market Trend

- Increased Focus on Adult Patients
- For a full, detailed list, view our report

Key Questions Answered in this Report

- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Companies Mentioned in this Report: Bristol-Myers Squibb, Baxter, Bluebird Bio, Daiichi Sankyo, Eli Lilly, Emmaus Medical, GlycoMimetics, HemaQuest Pharmaceuticals, Mast Therapeutics, Merck Sharp & Dohme, Pfizer, Selexys Pharmaceuticals

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 800-844-8156

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Aplastic Anemia - Pipeline Review, H1 2014
- Renal Anemia - Pipeline Review, H2 2014
- Iron Deficiency Anemia - Pipeline Review, H1 2014
- Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H1 2014
- Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2014